# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price target ...
Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price...
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $60...
CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and...
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $...
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $60...